IP Verse

Sandoz Ag competitive analysis

Latest oppositions filed by Sandoz Ag

Explore patent oppositions filed by Sandoz Ag against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026

Patent Number	Title	Applicant	Opposition Date
EP3677589	Improved Method For Producing Antibody-Drug Conjugate	DAIICHI SANKYO	Aug 25, 2026
EP4364724	High Concentration Vegf Receptor Fusion Protein Containing Formulations	REGENERON PHARMACEUTICALS	Aug 24, 2026
EP3500575	Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses Thereof	BEIGENE	Aug 3, 2026
EP4374919	Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	Jul 29, 2026
EP3834824	Method Of Treating Cancer Using Selective Estrogen Receptor Modulators	DUKE UNIVERSITY	Jul 14, 2026
EP3836920	Formulations Of Ag10	EIDOS THERAPEUTICS	Jun 30, 2026
EP4406594	Method Of Synthesizing Thyroid Hormone Analogs And Polymorphs Thereof	F HOFFMANN LA ROCHE	Jun 9, 2026
EP4185318	Extended, High Dose Vegf Antagonist Regimens For Treatment Of Angiogenic Eye Disorders	BAYER HEALTHCARE	Jun 1, 2026
EP3756650	Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione	AMGEN EUROPE	May 20, 2026
EP4188389	Methods Of Treating Chronic Kidney Disease With Dapagliflozin	ASTRAZENECA	May 12, 2026

Latest patents of Sandoz Ag opposed by its competitors

Explore Sandoz Ag's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026

Patent Number	Publication Date	Title	Total Oppositions
EP3829682	Dec 4, 2024	An Inhaler Device	1
EP3373914	Jun 1, 2022	Storage Stable Composition Comprising Rifaximin Alpha	1
EP3536311	Dec 22, 2021	Storage Stable Composition Comprising Rifaximin Alpha	1
EP3434265	Jul 7, 2021	Pharmaceutical Composition Containing Rifaximin Alpha & Delta	3
EP3390358	Sep 23, 2020	Crystalline Eravacycline Bis-Hydrochloride	1
EP3416627	Apr 22, 2020	Oral Dosage Form Comprising Rifaximin In Form Beta	1
EP2785702	Jan 22, 2020	Crystalline Dapagliflozin Hydrate	1
EP2975050	May 29, 2019	Quantification Of Misfolded Tnfr2:Fc	1
EP2977372	May 8, 2019	Polymorphs Of Febuxostat	1
EP2988733	Mar 27, 2019	Pharmaceutical Composition Containing Crystalline Macitentan	1

Latest PTAB cases involving Sandoz Ag

Discover the latest PTAB cases involving Sandoz Ag, highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 28, 2026

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Sandoz Ag
IPR2023-00478	Feb 3, 2023	SANDOZ	ACERTA PHARMA	Institution Denied
PGR2022-00054	Jul 29, 2022	SANDOZ	BIOGEN MA	Institution Denied
PGR2022-00037	May 2, 2022	SANDOZ	BOEHRINGER INGELHEIM	Institution Denied
IPR2019-00865	Mar 21, 2019	SANDOZ	PHARMACYCLICS	Final Written Decision
IPR2018-00156	Nov 6, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Institution Denied
IPR2018-00002	Oct 2, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Institution Denied
IPR2018-00002	Oct 2, 2017	SANDOZ	HOFFMAN	Institution Denied
IPR2017-02105	Sep 14, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Terminated-Settled
IPR2017-02105	Sep 14, 2017	SANDOZ	HOFFMAN	Terminated-Settled
IPR2017-02106	Sep 14, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Terminated-Settled

Peer Comparison New

IP litigation analysis comparing Sandoz Ag with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
SANDOZ	134	19	19	-
ABBVIE BIOTECHNOLOGY	-	-	-	22
BOEHRINGER INGELHEIM	33	187	8	9
NOVO NORDISK	9	127	1	9